# Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

> **NCT06935994** · PHASE2 · RECRUITING · sponsor: **Taichung Veterans General Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Metabolic Dysfunction Associated Steatotic Liver Disease

## Interventions

- **DRUG:** Aspirin 81 mg Enteric Coated Tab - 1 tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06935994
- **Lead sponsor:** Taichung Veterans General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-05
- **Primary completion:** 2028-12-31
- **Final completion:** 2032-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06935994

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06935994, "Aspirin for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT06935994. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*